Athira reports FY2021 net loss $54.9M; ACT-AD Phase 2 data on track for Q2 2022

LeonaBio, Inc.

Net loss $54.9M ($1.49/share) vs $19.9M in 2020; R&D spend $42.8M, up from $13.3M.
Cash & investments $319.7M as of Dec 31, 2021; cash used in ops $43.1M in 2021.
Topline ACT-AD Phase 2 Alzheimer's data expected Q2 2022; LIFT-AD Phase 3 enrollment to complete Q3 2022.
First patient dosed in SHAPE Phase 2 in Parkinson's dementia / DLB; ATH-1020 Phase 1 initiated.
Appointed Grant Pickering and Dr. Michael Panzara to Board; expanded management team.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.